 AIM ImmunoTech Inc NYSEAMERICAN:AIM CEO Thomas Equels told investors that the immuno-pharma company rounded out the first quarter by increasing its cash reserves to aggressively move forward with its clinical programs. As of March 31, 2021, the Ocala, Florida-based company had cash, cash equivalents, and marketable securities of 63.6 million, compared to 54.4 million as of December 31, 2020. 